New Chemotherapy-Free Lymphoma Therapy Listed on Australian PBS
Australian patients with relapsed or refractory follicular lymphoma now have access to a chemotherapy-free treatment option, following the inclusion of Minjuvi on the Pharmaceutical Benefits Scheme. The dual-targeted immunotherapy, which combines tafasitamab with rituximab and lenalidomide, aims to reduce the risk of disease progression for thousands of citizens.





















